Revelation Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for REVB, updated each market day.
REVB AI Sentiment
AI sees no strong directional signal for Revelation Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Revelation Biosciences, Inc. Common Stock
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
Sector
Exchange
Market Cap
$4,576,116
Cap Tier
Employees
9
Headquarters
SAN DIEGO, CA
Listed Since
Jan. 11, 2022
Website
REVB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
REVB Volatility
Revelation Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
